Clinical trial
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06104449 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 14, 2023
- Completion date
- April 17, 2026
- Enrollment
- 7 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic castration-resistant prostate cancer, prostatic neoplasms